Bipolar disorder (children) - aripirazole: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Bipolar disorder (children) - aripiprazole: evaluation report

01. Pre Meeting Briefing prepared by NICE

02. Submission from the technology manufacturer - Otsuka Phrmaceuticals

03. NICE request to the manufacturer for clarification on their submission

04. Manufacturer's clarification response

05. Consultee Submission - British Association of Psychopharmacology

06. Consultee Submission - Royal College of Nursing

07. Consultee Submission - Royal College of Paediatrics and Child Health

09. Clinical Expert personal perspective - James

10. Clinical Expert personal perspective - Coghill

11. Evidence Review Group Report prepared by School of Health Related Research

12. Evidence Review Group report - factual accuracy check

13. Evidence Review Group report - factual accuracy check corrections

This page was last updated: 06 June 2013